Also found in: Dictionary, Thesaurus, Wikipedia.


a nonsteroidal antiinflammatory drug of the cox-2 inhibitors group, administered orally for symptomatic treatment of arthritis.



Pharmacologic class: Nonsteroidal cyclooxygenase-2 (COX-2) inhibitor, nonsteroidal anti-inflammatory drug (NSAID)

Therapeutic class: Antirheumatic

Pregnancy risk category C

FDA Box Warning

• Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (which can be fatal). Risk may increase with duration of use, and may be greater in patients who have cardiovascular disease or risk factors for it.

• Drug is contraindicated for perioperative pain in setting of coronary artery bypass graft surgery.

• Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation, which can be fatal. These events can occur at any time during therapy and without warning. Elderly patients are at greater risk.


Exhibits anti-inflammatory, analgesic, and antipyretic action due to inhibition of COX-2 enzyme


Capsules: 50 mg, 100 mg, 200 mg, 400 mg

Indications and dosages

Ankylosing spondylitis, osteoarthritis
Adults: 200 mg/day P.O. as a single dose or 100 mg P.O. b.i.d.

Rheumatoid arthritis

Adults: 100 to 200 mg P.O. b.i.d.

Adjunctive treatment in familial adenomatous polyposis to decrease the number of adenomatous colorectal polyps

Adults: 400 mg P.O. b.i.d.

Acute pain or primary dysmenorrhea
Adults: 400 mg P.O. once, plus one additional 200 mg-dose as needed on first day; then 200 mg b.i.d. as needed

Juvenile rheumatoid arthritis
Children age 2 and older weighing 10 to 25 kg (22 to 55 lb): 50 mg P.O. b.i.d.
Children age 2 and older weighing 25 kg or more: 100 mg P.O. b.i.d.

Dosage adjustment

• Hepatic impairment
• Patients weighing less than 50 kg (110 lb)


• Hypersensitivity to drug, sulfonamides, or other NSAIDs
• Advanced renal disease
• Severe hepatic impairment
• Sensitivity precipitated by aspirin
• Third trimester of pregnancy
• Breastfeeding


Use cautiously in:
• renal insufficiency, hypertension
• history of asthma, urticaria, renal disease, hepatic dysfunction, heart failure
• patients on long-term NSAID therapy
• elderly patients
• pregnant patients in first or second trimester
• children younger than age 18 (safety not established).


• When administering doses higher than 200/mg daily, give with food or milk to improve drug absorption.

Adverse reactions

CNS: dizziness, drowsiness, headache, insomnia, fatigue, stroke

CV: angina, tachycardia, peripheral edema, myocardial infarction

EENT: ophthalmic effects, tinnitus, epistaxis, pharyngitis, rhinitis, sinusitis

GI: nausea, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, GI bleeding

GU: menorrhagia, renal failure

Hematologic: eosinophilia, ecchymosis, neutropenia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis, granulocytopenia, aplastic anemia, bone marrow depression

Hepatic: hepatotoxicity

Metabolic: hyperchloremia, hypophosphatemia

Musculoskeletal: back pain, leg cramps

Respiratory: upper respiratory tract infection

Skin: rash

Other: anaphylaxis


Drug-drug.Angiotensin-converting enzyme inhibitors, furosemide, thiazides: reduced celecoxib efficacy

Antacids containing aluminum and magnesium: decreased celecoxib blood level

Aspirin (regular doses): increased risk of GI bleeding and GI ulcers

Fluconazole, lithium: increased blood levels of these drugs

Warfarin: increased risk of bleeding

Drug-diagnostic tests.Alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen: increased levels

Hematocrit, hemoglobin: decreased values

Drug-herbs.Dong quai, feverfew, garlic, ginger, horse chestnut, red clover: increased risk of bleeding

White willow: increased risk of GI ulcers

Drug-behaviors.Long-term alcohol use, smoking: GI irritation and bleeding

Patient monitoring

• Monitor CBC, electrolyte levels, creatinine clearance, occult fecal blood test, and liver function test results every 6 to 12 months.

Patient teaching

Advise patient to immediately report bloody stools, vomiting of blood, or signs or symptoms of liver damage (nausea, fatigue, lethargy, pruritus, yellowing of eyes or skin, tenderness in upper right abdomen, or flulike symptoms).
• Instruct patient to take drug with food or milk.
• Tell patient to avoid aspirin and other NSAIDs (such as ibuprofen and naproxen) during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.


/cel·e·cox·ib/ (sel″ĕ-kok´sib) a nonsteroidal antiinflammatory drug that inhibits cyclooxygenase-1 activity, used for the treatment of osteoarthritis and rheumatoid arthritis.


A nonsteroidal anti-inflammatory drug, C17H14F3N3O2S, that selectively inhibits the formation of prostaglandins and is used primarily to treat pain and other symptoms of osteoarthritis, rheumatoid arthritis, and other joint and musculoskeletal conditions.


a nonsteroidal antiinflammatory drug of the cox-2 inhibitors group, administered orally for symptomatic treatment of arthritis.
References in periodicals archive ?
In a Two-Year Double-Blind Randomized Controlled Multicenter Study, Chondroitin Sulfate Was Significantly Superior to Celecoxib at Reducing Cartilage Loss with Similar Efficacy at Reducing Disease Symptoms in Knee Osteoarthritis Patients," presented by Jean-Pierre Pelletier, M.
5 Survey on Dosage Forms of Celecoxib in China, 2010-2014 6 Reference Price of Celecoxib in Chinese Hospitals in 2014 7 Major Manufacturers of Celecoxib in Chinese Market, 2010-2014 8 Market Outlook of Celecoxib in China, 2015-2019Companies Mentioned - Pfizer Inc; - Shire Plc For more information visit http://www.
2% in the celecoxib group fulfilled OMERACT-OARSI criteria.
In a group contraindicated or relatively contraindicated to celecoxib, "you get similar efficacy [with Droglican] at 6 months," he said in an interview.
Each of these generic companies previously filed an abbreviated new drug application with the United States Food and Drug Administration seeking approval to market a generic form of celecoxib in the United States beginning in May 2014, prior to the December 2, 2015 expiration of the reissue patent.
Since there also appears to be involvement of oxidative stress in osteoarthritis via different mechanisms, the interaction of celecoxib and silymarin (an antioxidant constituent from Silybum marianum) was studied on experimentally induced osteoarthritis in rats.
The drug did not alter the number of lesions appearing after two months of treatment, but by the end of the trial participants taking celecoxib had significantly fewer nonmelanoma skin cancers than those given a placebo pill.
Both rofecoxib and celecoxib were each used by about 2% (total exceeds 45% because some people used more than one NSAID).
The Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT), sponsored by the National Institute on Aging, was a placebo-controlled clinical trial designed to assess naproxen and celecoxib in 2,528 cognitively normal men and women aged 70 or older.
He concludes that studies on celecoxib and other NSAIDs have suggested that any risk with coxibs is likely to be small and comparable to traditional NSAIDs.
The first of the COX-2 selective inhibitors, celecoxib, was approved based on the results of five clinical trials involving more than 5200 patients with OA or RA, in which its efficacy and toxicity were compared to those of NS-NSAIDs and placebo.
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil